María Pilar
Garrido López
Profesor/a Asociado/a en CC. de la Salud
Aix-Marseille University
Marsella, FranciaPublicacions en col·laboració amb investigadors/es de Aix-Marseille University (5)
2024
-
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356
2023
-
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476
2022
-
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
Journal of Thoracic Oncology, Vol. 17, Núm. 5, pp. 661-674
-
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Clinical Cancer Research, Vol. 28, Núm. 12, pp. 2506-2516
2017
-
Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial
JAMA - Journal of the American Medical Association, Vol. 317, Núm. 18, pp. 1844-1853